Centchroman

Drug Profile

Centchroman

Alternative Names: Centron; Choice-7; Ormeloxifene; Saheli; Sevista (centchroman)

Latest Information Update: 21 Aug 2007

Price : $50

At a glance

  • Originator Central Drug Research Institute
  • Class Chromans; Contraceptives; Pyrrolidines; Small molecules
  • Mechanism of Action Estrogen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Contraception
  • Phase Unknown Metrorrhagia

Most Recent Events

  • 31 Dec 2006 Investigation in Metrorrhagia in India (PO)
  • 16 Jul 2001 A study in volunteers has been added to the adverse events and pharmacokinetics sections
  • 28 May 1998 A study in patients with breast cancer has been added to the therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top